Anti-TM4SF4 Antibody

About Algok Bio

Algok Bio is a private, preclinical-stage biotech company operating as a specialized asset developer, bridging the gap between early discovery and commercialization. The company's core strategy involves in-licensing or acquiring promising therapeutic leads, particularly those ready for preclinical studies, and advancing them through development using its team's proven expertise. Its current pipeline is anchored by idetrexed, a clinical-stage folate receptor-targeted therapy for ovarian cancer, alongside earlier-stage antibody candidates. Algok Bio's model is designed to de-risk asset acquisition for larger pharma partners by providing rigorous lead identification and development execution.

Therapeutic Areas

Other Not Specified (Oncology) Drugs